Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
velaglucerase alfa (VPRIV®)
Reference No. 571
Publication date:
25/07/2014
Appraisal information
velaglucerase alfa (VPRIV®) 400 units powder for solution for infusion
Company:
Shire Pharmaceuticals Ltd
BNF category:
Nutrition and blood
NMG meeting date:
14/05/2014
AWMSG meeting date:
11/06/2014
Submission Type:
Full Submission
Status:
Recommended
Advice No:
1214
Ministerial ratification:
24/07/2014
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification
AWMSG advice
Velaglucerase alfa (VPRIV®) is recommended as an option for use within NHS Wales for long-term enzyme replacement therapy in patients with type 1 Gaucher disease. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
velaglucerase alfa (VPRIV) 571 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
velaglucerase alfa (VPRIV) 571 ASAR
Clinical Expert (CE) Summary
Download
velaglucerase alfa (VPRIV) 571 CE Summary
